DK2699553T3 - Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed - Google Patents

Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed Download PDF

Info

Publication number: DK2699553T3
Authority: DK; Denmark
Prior art keywords: compositions; processes; treatment; diaminocarboxamide; substituted
Prior art date: 2011-04-22

Application number

DK12718524.7T

Other languages

English (en)

Inventor

Brydon L Bennett

Paul Erdman

Robert Hilgraf

Laurie Ann Lebrun

Meg Mccarrick

Stephen Norris

David A Paisner

Marianne Sloss

William J Romanow

Yoshitaka Satoh

Jayashree Tikhe

Won Hyung Yoon

Jan Elsner

Mehran F Moghaddam

Mark A Nagy

Maria Mercedes Delgado

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-22

Filing date

2012-04-20

Publication date

2024-01-29

2012-04-20 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2024-01-29 Application granted granted Critical

2024-01-29 Publication of DK2699553T3 publication Critical patent/DK2699553T3/da

Links

239000000203 mixture Substances 0.000 title 1
CTAWBMDQTAZKIE-UHFFFAOYSA-N n,n-diaminoformamide Chemical class NN(N)C=O CTAWBMDQTAZKIE-UHFFFAOYSA-N 0.000 title 1
150000003230 pyrimidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)

DK12718524.7T 2011-04-22 2012-04-20 Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed DK2699553T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161478076P	2011-04-22	2011-04-22
US201161555339P	2011-11-03	2011-11-03
PCT/US2012/034349 WO2012145569A1 (en)	2011-04-22	2012-04-20	Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number	Publication Date
DK2699553T3 true DK2699553T3 (da)	2024-01-29

Family

ID=46025954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12718524.7T DK2699553T3 (da)	2011-04-22	2012-04-20	Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed

Country Status (35)

Country	Link
US (7)	US9139534B2 (da)
EP (2)	EP4328223A3 (da)
JP (5)	JP6027095B2 (da)
KR (2)	KR101962488B1 (da)
CN (5)	CN103492370B (da)
AR (1)	AR087151A1 (da)
AU (1)	AU2012245387C1 (da)
BR (1)	BR112013022813B1 (da)
CA (1)	CA2829264C (da)
CL (1)	CL2013003025A1 (da)
CO (1)	CO6821941A2 (da)
CR (1)	CR20130490A (da)
DK (1)	DK2699553T3 (da)
EC (1)	ECSP13012985A (da)
ES (1)	ES2968700T3 (da)
FI (1)	FI2699553T3 (da)
HR (1)	HRP20240097T1 (da)
HU (1)	HUE064883T2 (da)
IL (3)	IL228721A (da)
LT (1)	LT2699553T (da)
MX (1)	MX351754B (da)
NI (1)	NI201300113A (da)
PE (1)	PE20140502A1 (da)
PH (2)	PH12013501921A1 (da)
PL (1)	PL2699553T3 (da)
PT (1)	PT2699553T (da)
RS (1)	RS65202B1 (da)
RU (2)	RU2697712C2 (da)
SG (2)	SG10201702654VA (da)
SI (1)	SI2699553T1 (da)
SM (1)	SMT202400031T1 (da)
TW (3)	TWI548621B (da)
UA (1)	UA120740C2 (da)
WO (1)	WO2012145569A1 (da)
ZA (1)	ZA201306471B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2697712C2 (ru) *	2011-04-22	2019-08-19	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
BR112015009798A2 (pt)	2012-11-08	2017-07-11	Bristol Myers Squibb Co	compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
KR102243637B1 (ko)	2013-03-14	2021-04-26	리커리엄 아이피 홀딩스, 엘엘씨	바이사이클릭 진통 화합물
WO2015039613A1 (zh) *	2013-09-18	2015-03-26	北京韩美药品有限公司	抑制btk和/或jak3激酶活性的化合物
BR112016012728A2 (pt)	2013-12-05	2020-08-11	Pharmacyclics Llc	compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
CN108947867A (zh)	2013-12-12	2018-12-07	卡利拉制药公司	双环烷基化合物及合成
US9556126B2 (en) *	2013-12-20	2017-01-31	Signal Pharmaceuticals, Llc	Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3114107B1 (en)	2014-03-07	2020-07-22	Recurium IP Holdings, LLC	Propellane derivates and synthesis
US10308609B2 (en)	2014-09-17	2019-06-04	Zeno Royalties & Milestones, LLC	Bicyclic compounds
US9796685B2 (en) *	2014-12-16	2017-10-24	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3233808B1 (en) *	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en)	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6805232B2 (ja) *	2015-07-24	2020-12-23	セルジーンコーポレイション	（１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
WO2018019244A1 (zh) *	2016-07-27	2018-02-01	广东东阳光药业有限公司	2,6-二甲基嘧啶酮衍生物的盐及其用途
WO2018029336A1 (en)	2016-08-12	2018-02-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
WO2018049353A1 (en) *	2016-09-12	2018-03-15	Imago Pharmaceuticals, Inc.	Treatment of fibrotic disorders with jun n-terminal kinase inhibitors
BR112019011740A2 (pt)	2016-12-09	2019-10-29	Cadila Healthcare Ltd	composição farmacêutica e método para o tratamento de colangite biliar primária
US11242327B2 (en)	2017-05-15	2022-02-08	Recurium Ip Holdings, Llc	Analgesic compounds
IL301709B2 (en)	2017-08-09	2025-07-01	Denali Therapeutics Inc	Compounds, compositions and methods
PL3676297T3 (pl)	2017-09-01	2023-12-11	Denali Therapeutics Inc.	Związki, kompozycje i sposoby
CN107573249B (zh) *	2017-09-25	2018-12-25	上海馨远医药科技有限公司	一种反式4-烷氧基环己胺的制备方法
AR113820A1 (es)	2017-11-01	2020-06-17	Bristol Myers Squibb Co	Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
KR20210126036A (ko)	2019-02-13	2021-10-19	데날리 테라퓨틱스 인크.	화합물, 조성물 및 방법
MA54959A (fr)	2019-02-13	2021-12-22	Denali Therapeutics Inc	Composés, compositions et procédés
CN111718332B (zh) *	2019-03-19	2021-08-17	北京赛特明强医药科技有限公司	2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
JP2022539208A (ja)	2019-07-03	2022-09-07	スミトモファーマオンコロジー，インコーポレイテッド	チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
WO2021025975A1 (en) *	2019-08-06	2021-02-11	Eli Lilly And Company	Pyrimidine-5-carboxamide compound
CN112574123B (zh) *	2019-09-30	2024-06-11	武汉朗来科技发展有限公司	Jnk抑制剂、其药物组合物和用途
CA3170252A1 (en) *	2020-03-06	2021-09-10	Chun-Ping Chang	Pyrimidine compounds and their pharmaceutical uses
CN113698408B (zh) *	2020-05-22	2025-07-25	武汉朗来科技发展有限公司	Jnk抑制剂、其药物组合物和用途
CN115003671B (zh) *	2020-09-07	2024-08-06	武汉朗来科技发展有限公司	Jnk抑制剂、其药物组合物和用途
EP4240362A4 (en) *	2020-11-09	2024-10-23	Merck Sharp & Dohme LLC	Diaminopyrimidine carboxamide inhibitors of hpk1
US20240360125A9 (en) *	2021-02-22	2024-10-31	The Trustees Of Princeton University	2-substituted bicyclo[1.1.1]pentanes
WO2023108536A1 (en) *	2021-12-16	2023-06-22	Lynk Pharmaceuticals Co. Ltd.	Tyk2 inhibitors and compositions and methods thereof
CN118401516A (zh)	2021-12-16	2024-07-26	凌科药业(杭州)有限公司	Tyk2抑制剂及其组合物和方法
CN114315738B (zh) *	2022-01-15	2023-08-18	重庆东寰科技开发有限公司	一种2,4-二氨基嘧啶-3-氧化物的制备方法
US20240165112A1 (en)	2022-11-04	2024-05-23	Bristol-Myers Squibb Company	Therapy for the treatment of cancer
CN120463687A (zh) *	2022-12-30	2025-08-12	杭州矩阵生物药业有限公司	具有jnk抑制活性的嘧啶类衍生物及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH549339A (de)	1971-05-12	1974-05-31	Ciba Geigy Ag	Herbizides mittel.
US4301281A (en) *	1979-04-18	1981-11-17	American Home Products Corporation	7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]-pyrimidine-6-carboxylic acid amides
DE3338859A1 (de) *	1983-10-26	1985-05-09	Bayer Ag, 5090 Leverkusen	Substituierte pyrimidine
DE69839338T2 (de) *	1997-02-05	2008-07-10	Warner-Lambert Company Llc	Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
WO1999031073A1 (fr) *	1997-12-15	1999-06-24	Yamanouchi Pharmaceutical Co., Ltd.	Nouveaux derives de pyrimidine-5-carboxamide
WO1999061444A2 (en)	1998-05-26	1999-12-02	Warner-Lambert Company	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ATE342892T1 (de)	1998-08-29	2006-11-15	Astrazeneca Ab	Pyrimidine verbindungen
AU5107900A (en)	1999-06-09	2000-12-28	Yamanouchi Pharmaceutical Co., Ltd.	Novel heterocyclic carboxamide derivatives
JP4622047B2 (ja)	1999-06-09	2011-02-02	アステラス製薬株式会社	新規なヘテロ環カルボキサミド誘導体
AU5108000A (en)	1999-06-10	2001-01-02	Yamanouchi Pharmaceutical Co., Ltd.	Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US6498165B1 (en)	1999-06-30	2002-12-24	Merck & Co., Inc.	Src kinase inhibitor compounds
GB0016877D0 (en) *	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
JP4329290B2 (ja) *	2000-10-06	2009-09-09	田辺三菱製薬株式会社	脂肪族含窒素五員環化合物
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
WO2003082855A1 (fr)	2002-03-28	2003-10-09	Kyowa Hakko Kogyo Co., Ltd.	Agent anti-inflammatoire
CN1310916C (zh)	2002-06-25	2007-04-18	协和发酵工业株式会社	双环类杂环化合物
ATE530530T1 (de)	2002-06-28	2011-11-15	Astellas Pharma Inc	Diaminopyrimidincarbonsäureamidderivat
DK1534286T3 (da)	2002-07-29	2010-04-26	Rigel Pharmaceuticals Inc	Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
AU2003291670A1 (en) *	2002-11-01	2004-06-07	Abbott Laboratories	Anti-infective agents
US7902203B2 (en)	2002-11-01	2011-03-08	Abbott Laboratories, Inc.	Anti-infective agents
JPWO2004054617A1 (ja)	2002-12-13	2006-04-20	協和醗酵工業株式会社	中枢疾患の予防および／または治療剤
WO2004065378A1 (en)	2003-01-17	2004-08-05	Warner-Lambert Company Llc	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
ATE440087T1 (de) *	2003-01-30	2009-09-15	Boehringer Ingelheim Pharma	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
KR100864393B1 (ko) *	2003-04-10	2008-10-20	에프. 호프만-라 로슈 아게	피리미도 화합물
EP1518655A1 (en) *	2003-07-24	2005-03-30	John Palmer Corp.	Apparatus for and process of gas-assisted injection molding of plastics material
CA2533320A1 (en)	2003-08-15	2006-02-24	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06003207A (es)	2003-09-24	2006-06-23	Wyeth Corp	5-arilpirimidinas como agentes anti-cancer.
US7253204B2 (en) *	2004-03-26	2007-08-07	Methylgene Inc.	Inhibitors of histone deacetylase
US7956060B2 (en) *	2004-03-30	2011-06-07	Kyowa Hakko Kirin Co., Ltd.	Pyrimidine derivative compound
US7601714B2 (en) *	2004-07-08	2009-10-13	Boehringer Ingelheim Pharmaceuticals, Inc.	Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2006027378A1 (en)	2004-09-10	2006-03-16	Altana Pharma Ag	Roflumilast and syk inhibitor combination and methods of use thereof
CA2579007A1 (en)	2004-09-10	2006-03-16	Altana Pharma Ag	Ciclesonide and syk inhibitor combination and methods of use thereof
MX2007003796A (es)	2004-09-30	2007-04-25	Tibotec Pharm Ltd	Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
AU2006223199A1 (en)	2005-03-10	2006-09-21	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2007023110A2 (en) *	2005-08-25	2007-03-01	F. Hoffmann-La Roche Ag	P38 map kinase inhibitors and methods for using the same
WO2007032445A1 (ja)	2005-09-16	2007-03-22	Kyowa Hakko Kogyo Co., Ltd.	タンパク質キナーゼ阻害剤
EP1931667A1 (en) *	2005-09-28	2008-06-18	Ranbaxy Laboratories Limited	Pyrido-pyridimidine derivatives useful as antiinflammatory agents
CA2633992A1 (en) *	2005-12-21	2007-07-05	Boehringer Ingelheim International Gmbh	Pyrimidine derivatives useful as inhibitors of pkc-theta
US20100010025A1 (en) *	2006-07-21	2010-01-14	Norvartis Ag	Pyrimidine Derivatives
US8188113B2 (en)	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20080139531A1 (en)	2006-12-04	2008-06-12	Alcon Manufacturing Ltd.	Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
UA97834C2 (ru)	2007-04-18	2012-03-26	Пфайзер Продактс Инк.	Производные сульфониламида для лечения анормального роста клеток
NZ581397A (en)	2007-04-27	2012-02-24	Astrazeneca Ab	Pyrimidine compounds for the inhibition of Eph receptors and for the treatment of cancer
EP2183242A2 (en)	2007-07-16	2010-05-12	AstraZeneca AB	Pyrimidine derivatives 934
BRPI0814432A2 (pt)	2007-07-17	2017-05-09	Rigel Pharmaceuticals Inc	pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
NZ589315A (en) *	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
VN29259A1 (en) *	2008-04-16	2012-04-25	Portola Pharm Inc	2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
CA2723205C (en) *	2008-04-16	2017-03-14	Portola Pharmaceuticals, Inc.	2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
CN102066338A (zh)	2008-04-22	2011-05-18	波托拉医药品公司	蛋白激酶抑制剂
EA201001669A1 (ru)	2008-04-22	2011-06-30	Астразенека Аб	Замещенные пиримидин-5-карбоксамиды 281
JP5302389B2 (ja) *	2008-04-29	2013-10-02	エフ．ホフマン−ラロシュアーゲー	Ｊｎｋのピリミジニルピリドンインヒビター
ES2645689T5 (en)	2008-05-21	2025-06-24	Takeda Pharmaceuticals Co	Phosphorous derivatives as kinase inhibitors
PE20100087A1 (es)	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
AU2009262068C1 (en)	2008-06-27	2015-07-02	Celgene Car Llc	Heteroaryl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010024430A1 (ja) *	2008-09-01	2010-03-04	アステラス製薬株式会社	2,4-ジアミノピリミジン化合物
TWI453207B (zh)	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法
US20110166161A1 (en)	2008-09-18	2011-07-07	Astellas Pharma Inc.	Heterocyclic carboxamide compounds
US20100137313A1 (en)	2008-10-03	2010-06-03	Astrazeneca Ab	Heterocyclic derivatives and methods of use thereof
WO2010046273A2 (en) *	2008-10-22	2010-04-29	F. Hoffmann-La Roche Ag	Pyrimidinyl pyridone inhibitors of jnk
KR101712085B1 (ko)	2008-10-31	2017-03-03	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화
CA2745970A1 (en) *	2008-12-12	2010-06-17	Msd K.K.	Dihydropyrimidopyrimidine derivative
US8809538B2 (en)	2009-01-12	2014-08-19	Array Biopharma Inc.	Piperidine-containing compounds and use thereof
WO2010097248A1 (en)	2009-01-13	2010-09-02	Glaxo Group Limited	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010090875A1 (en) *	2009-01-21	2010-08-12	Rigel Pharmaceuticals, Inc.	Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
WO2010129802A1 (en) *	2009-05-06	2010-11-11	Portola Pharmaceuticals, Inc.	Inhibitors of jak
JP2012148977A (ja) *	2009-05-20	2012-08-09	Astellas Pharma Inc	アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
EP2440145A4 (en) *	2009-06-08	2013-12-11	Reduction Technologies Inc	SYSTEMS, METHODS AND DEVICES FOR VERTEBRAL DEFORMATION CORRECTION
CN102498110A (zh) *	2009-06-10	2012-06-13	雅培制药有限公司	作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko)	2009-11-30	2011-06-03	주식회사 오스코텍	피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CA2780759A1 (en)	2009-12-01	2011-06-09	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
JP2011173853A (ja) *	2010-02-26	2011-09-08	Astellas Pharma Inc	置換アミノアダマンチルアルキル基を有する２，４−ジアミノピリミジン化合物
EP2595982B1 (en)	2010-07-21	2018-06-13	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
US20130252917A1 (en)	2010-09-30	2013-09-26	Portola Pharmaceuticals, Inc.	Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
WO2012044936A1 (en)	2010-09-30	2012-04-05	Portola Pharmaceuticals, Inc.	Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
RU2697712C2 (ru) *	2011-04-22	2019-08-19	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
US9556126B2 (en) *	2013-12-20	2017-01-31	Signal Pharmaceuticals, Llc	Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en) *	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3233808B1 (en) *	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
US9796685B2 (en) *	2014-12-16	2017-10-24	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide

2012
- 2012-04-20 RU RU2017121958A patent/RU2697712C2/ru active
- 2012-04-20 PE PE2013002388A patent/PE20140502A1/es active IP Right Grant
- 2012-04-20 FI FIEP12718524.7T patent/FI2699553T3/fi active
- 2012-04-20 TW TW101114317A patent/TWI548621B/zh active
- 2012-04-20 EP EP23205984.0A patent/EP4328223A3/en not_active Withdrawn
- 2012-04-20 ES ES12718524T patent/ES2968700T3/es active Active
- 2012-04-20 CN CN201280019861.3A patent/CN103492370B/zh active Active
- 2012-04-20 EP EP12718524.7A patent/EP2699553B1/en active Active
- 2012-04-20 HU HUE12718524A patent/HUE064883T2/hu unknown
- 2012-04-20 US US13/451,574 patent/US9139534B2/en active Active
- 2012-04-20 DK DK12718524.7T patent/DK2699553T3/da active
- 2012-04-20 AU AU2012245387A patent/AU2012245387C1/en active Active
- 2012-04-20 RS RS20240075A patent/RS65202B1/sr unknown
- 2012-04-20 SG SG10201702654VA patent/SG10201702654VA/en unknown
- 2012-04-20 KR KR1020137027371A patent/KR101962488B1/ko active Active
- 2012-04-20 MX MX2013010946A patent/MX351754B/es active IP Right Grant
- 2012-04-20 UA UAA201313555A patent/UA120740C2/uk unknown
- 2012-04-20 RU RU2013152021A patent/RU2625309C2/ru active
- 2012-04-20 CN CN202010398589.0A patent/CN111499580A/zh active Pending
- 2012-04-20 KR KR1020197007112A patent/KR102055532B1/ko active Active
- 2012-04-20 PT PT127185247T patent/PT2699553T/pt unknown
- 2012-04-20 WO PCT/US2012/034349 patent/WO2012145569A1/en active Application Filing
- 2012-04-20 CA CA2829264A patent/CA2829264C/en active Active
- 2012-04-20 SM SM20240031T patent/SMT202400031T1/it unknown
- 2012-04-20 JP JP2014506559A patent/JP6027095B2/ja active Active
- 2012-04-20 HR HRP20240097TT patent/HRP20240097T1/hr unknown
- 2012-04-20 CN CN202010398710.XA patent/CN111471021B/zh active Active
- 2012-04-20 PL PL12718524.7T patent/PL2699553T3/pl unknown
- 2012-04-20 CN CN201510389071.XA patent/CN105001165B/zh active Active
- 2012-04-20 CN CN201610882236.1A patent/CN106946795B/zh active Active
- 2012-04-20 SG SG2013074273A patent/SG194086A1/en unknown
- 2012-04-20 SI SI201232053T patent/SI2699553T1/sl unknown
- 2012-04-20 LT LTEPPCT/US2012/034349T patent/LT2699553T/lt unknown
- 2012-04-20 TW TW105112041A patent/TWI599563B/zh active
- 2012-04-20 BR BR112013022813A patent/BR112013022813B1/pt active IP Right Grant
- 2012-04-20 PH PH1/2013/501921A patent/PH12013501921A1/en unknown
- 2012-04-20 TW TW106120278A patent/TWI681952B/zh active
- 2012-04-23 AR ARP120101402 patent/AR087151A1/es active IP Right Grant
2013
- 2013-08-28 ZA ZA2013/06471A patent/ZA201306471B/en unknown
- 2013-09-26 CR CR20130490A patent/CR20130490A/es unknown
- 2013-10-03 IL IL228721A patent/IL228721A/en active IP Right Grant
- 2013-10-08 CO CO13238970A patent/CO6821941A2/es active IP Right Grant
- 2013-10-18 CL CL2013003025A patent/CL2013003025A1/es unknown
- 2013-10-21 NI NI201300113A patent/NI201300113A/es unknown
- 2013-10-21 EC ECSP13012985 patent/ECSP13012985A/es unknown
2015
- 2015-07-29 PH PH12015501677A patent/PH12015501677A1/en unknown
- 2015-07-31 US US14/814,633 patent/US9701643B2/en active Active
2016
- 2016-05-23 IL IL245792A patent/IL245792B/en active IP Right Grant
- 2016-10-13 JP JP2016202099A patent/JP6502302B2/ja active Active
2017
- 2017-06-07 US US15/616,039 patent/US10040770B2/en active Active
- 2017-06-15 IL IL252952A patent/IL252952B/en active IP Right Grant
2018
- 2018-06-28 US US16/021,415 patent/US10266500B2/en active Active
2019
- 2019-03-04 US US16/291,193 patent/US10919865B2/en active Active
- 2019-03-20 JP JP2019052826A patent/JP6898961B2/ja active Active
2020
- 2020-12-29 US US17/136,276 patent/US11325890B2/en active Active
2021
- 2021-06-11 JP JP2021098226A patent/JP7374955B2/ja active Active
2022
- 2022-03-29 US US17/707,471 patent/US12129237B2/en active Active
2023
- 2023-10-25 JP JP2023183330A patent/JP2023179797A/ja active Pending

Also Published As

Publication number	Publication date
AU2012245387C1 (en)	2016-05-05
HRP20240097T1 (hr)	2024-03-29
US20180305322A1 (en)	2018-10-25
NZ614776A (en)	2015-06-26
CN106946795B (zh)	2020-06-02
TW201627291A (zh)	2016-08-01
CN106946795A (zh)	2017-07-14
US20190194144A1 (en)	2019-06-27
US20150336901A1 (en)	2015-11-26
KR101962488B1 (ko)	2019-03-26
TW201311651A (zh)	2013-03-16
US20130029987A1 (en)	2013-01-31
RU2697712C2 (ru)	2019-08-19
AU2012245387A1 (en)	2013-03-28
CN111471021A (zh)	2020-07-31
RS65202B1 (sr)	2024-03-29
PT2699553T (pt)	2024-01-24
US10919865B2 (en)	2021-02-16
MX351754B (es)	2017-10-27
CR20130490A (es)	2014-01-14
FI2699553T3 (fi)	2024-01-24
CN103492370A (zh)	2014-01-01
IL252952A0 (en)	2017-08-31
JP2023179797A (ja)	2023-12-19
JP2017002091A (ja)	2017-01-05
US20170267647A1 (en)	2017-09-21
RU2013152021A (ru)	2015-05-27
US11325890B2 (en)	2022-05-10
CN111499580A (zh)	2020-08-07
AR087151A1 (es)	2014-02-26
WO2012145569A1 (en)	2012-10-26
RU2017121958A (ru)	2019-01-29
LT2699553T (lt)	2024-02-12
HUE064883T2 (hu)	2024-04-28
EP2699553A1 (en)	2014-02-26
PH12015501677B1 (en)	2015-10-05
TWI681952B (zh)	2020-01-11
TWI548621B (zh)	2016-09-11
RU2017121958A3 (da)	2019-01-29
TWI599563B (zh)	2017-09-21
US9701643B2 (en)	2017-07-11
US12129237B2 (en)	2024-10-29
JP2014514322A (ja)	2014-06-19
NI201300113A (es)	2014-02-25
EP2699553B1 (en)	2023-11-08
ECSP13012985A (es)	2013-11-29
CN111471021B (zh)	2024-04-02
ES2968700T3 (es)	2024-05-13
RU2625309C2 (ru)	2017-07-13
CO6821941A2 (es)	2013-12-31
AU2012245387B2 (en)	2015-07-09
BR112013022813A2 (pt)	2016-08-02
SG10201702654VA (en)	2017-06-29
US20230116093A1 (en)	2023-04-13
PH12015501677A1 (en)	2015-10-05
PE20140502A1 (es)	2014-05-02
BR112013022813B1 (pt)	2022-04-19
JP2021138755A (ja)	2021-09-16
TW201736348A (zh)	2017-10-16
EP4328223A3 (en)	2024-11-06
CN105001165A (zh)	2015-10-28
IL228721A0 (en)	2013-12-31
PH12013501921A1 (en)	2013-11-25
IL252952B (en)	2020-02-27
EP4328223A2 (en)	2024-02-28
CA2829264A1 (en)	2012-10-26
JP6898961B2 (ja)	2021-07-07
CN103492370B (zh)	2016-10-26
SG194086A1 (en)	2013-11-29
IL245792B (en)	2018-03-29
PL2699553T3 (pl)	2024-03-25
UA120740C2 (uk)	2020-02-10
US9139534B2 (en)	2015-09-22
CL2013003025A1 (es)	2014-05-30
JP6027095B2 (ja)	2016-11-16
US20210114992A1 (en)	2021-04-22
US10040770B2 (en)	2018-08-07
JP7374955B2 (ja)	2023-11-07
IL228721A (en)	2016-06-30
KR20190029772A (ko)	2019-03-20
SMT202400031T1 (it)	2024-03-13
CA2829264C (en)	2020-04-07
US10266500B2 (en)	2019-04-23
KR102055532B1 (ko)	2019-12-12
KR20140027160A (ko)	2014-03-06
MX2013010946A (es)	2013-12-16
IL245792A0 (en)	2016-06-30
JP2019112457A (ja)	2019-07-11
CN105001165B (zh)	2020-06-23
ZA201306471B (en)	2014-12-23
SI2699553T1 (sl)	2024-03-29
JP6502302B2 (ja)	2019-04-17

Publication	Publication Date	Title
DK2699553T3 (da)	2024-01-29	Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2776567T3 (da)	2021-04-26	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2726511T3 (da)	2019-09-23	Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser
DK2763665T3 (da)	2019-11-18	Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3252160T3 (da)	2021-02-01	Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK3421051T3 (da)	2020-06-22	Fremgangsmåder til glycokonjugering og sammensætninger
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2884999T3 (da)	2021-01-04	Fremgangsmåde og sammensætninger til cellulær immunterapi
DK2890780T3 (da)	2020-09-21	Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2920149T3 (da)	2019-07-01	3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2729151T3 (da)	2021-06-28	Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2699397T3 (da)	2017-11-20	Apparater, system og fremgangsmåder til at danne pressede artikler og pressede artikler dannet derved
DK2741763T3 (da)	2016-02-15	Sammensætning til kontrolleret ovariestimulering.
DK2967049T3 (da)	2020-12-07	Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK2830654T3 (da)	2019-08-26	Metoder og sammensætninger til behandling af inflammation
BR112014004192A2 (pt)	2017-10-31	composição de tratamento de sementes, e, método de tratamento de sementes
BR112013022306A2 (pt)	2016-12-06	método, e, composição
DK3175852T3 (da)	2019-05-27	Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK2877736T3 (da)	2021-01-11	Skrue, skruedel og fremgangsmåde dertil
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
BR112013030897A2 (pt)	2017-06-06	composição.
LT2683245T (lt)	2020-03-25	Būdai ir kompozicijos, skirti depresijai gydyti panaudojant ciklobenzapriną
DK2892556T3 (da)	2019-08-05	Sammensætninger og fremgangsmåder til behandling af sygdomme
BR112013019224A2 (pt)	2016-10-11	composição, e metodo
EP2807256A4 (en)	2015-10-28	MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE